Scorpion scores $65M as it lines up a partner to take EGFR programs global
Axel Hoos is firing up another cylinder in pursuit of Scorpion Therapeutics’ vision for precision oncology 2.0, and it involves bringing a European player to his corner.
Scorpion will earn $65 million in upfront and near-term milestones for teaming up with French pharma Pierre Fabre to co-develop and commercialize two of its preclinical programs that are slated for IND filings over the next year. While the partners each take the lead on one of the programs, the commercial rights will be split by geography, with Scorpion keeping rights in the US, Canada and Japan while Pierre Fabre takes charge everywhere else.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.